Other combinations with anti-PD-L1 and anti-CTLA4 have been explored in the MYSTIC study, in which patients with advanced NSCLC were randomized to receive durvalumab (anti-PD-L1) versus durvalumab and tremelimumab (anti-CTLA-4) versus platinum-based CT. The gene discussed is CD274; the disease is non-small cell lung carcinoma.